Skip to main content

Market Overview

Opdivo Plus Cabometyx Combo Shows Superior Clinical Benefit Versus Sunitinib In Late-Stage Kidney Cancer Study

  • Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) have announced updated data from Phase 3 CheckMate 9ER trial, evaluating the combination of former's Opdivo (nivolumab) and latter's Cabometyx (cabozantinib) drug compared to Pfizer Inc's (NYSE: PFE) Sutent (sunitinib) in the first-line treatment of advanced renal cell carcinoma.
  • BMY will present the data at the virtual American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium.
  • With a median follow-up of two years (23.5 months), Opdivo, combined with Cabometyx, doubled median progression-free survival (17.0 months vs. 8.3 months) compared to sunitinib, the trial's primary endpoint.
  • Almost twice as many patients responded to the combination treatment vs. sunitinib (54.8% vs. 28.4%). Opdivo plus Cabometyx demonstrated a 34% reduction in the risk of death compared to sunitinib.
  • In an exploratory analysis, the combination was associated with a disease control rate of 88.2% vs. 69.9% compared to sunitinib.
  • 6.6% of patients discontinued treatment in the combination arm due to adverse events, compared to 9.7% in Opdivo only and 7.2% discontinued in Cabometyx.
  • In a subgroup analysis of 75 patients with sarcomatoid features, the combination reduced the risk of death by 64% vs. sunitinib and demonstrating better progression-free survival (10.3 months vs. 4.2 months) and overall response rate (55.9% vs. 22.0%).
  • Price Action: In the premarket session on the last check Tuesday, EXEL shares are trading 1.4% higher at 24.45, and BMY is up 0.42% at $60.48. PFE shares are marginally higher by 0.09% at $34.85.

Related Articles (EXEL + BMY)

View Comments and Join the Discussion!

Posted-In: Kidney Diseases Phase 3Biotech News FDA Top Stories General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at